- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07944391
Acceptance and Commitment Therapy for Mesh Injury: A HSCED Series
The Mesh Scandal: Acceptance and Commitment Therapy for Psychological Distress in Mesh Injured Women. A Hermeneutic Single-Case Efficacy Design Series.
The Patient Safety Commissioner estimates that at least 10,000 women in England have experienced significant harm resulting from vaginal mesh implants. Adverse effects resulting in psychological distress and reduced quality of life have been reported. The purpose of the study is to explore the efficacy of Acceptance and Commitment Therapy (ACT) for women with mesh injury experiencing psychological distress.
The study will use a Hermeneutic Single-Case Efficacy Design to answer the primary and secondary objectives.
Primary objective: To investigate whether ACT is an effective therapeutic intervention for women experiencing psychological distress due to mesh injury.
Secondary objectives: To determine whether there are any meaningful changes throughout the ACT intervention; whether these changes can be attributed to the ACT intervention and what factors contribute to the changes.
Participants will undergo a ten-session ACT intervention and follow-up session. A qualitative interview will be carried out to explore the change experience.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
NICE guidelines recognise the physical and psychological impact of mesh complications and recommends that psychological and psychosexual support is offered to women affected. Despite this, a therapeutic intervention for mesh complications has not yet been explored. Acceptance and Commitment Therapy (ACT) as been empirically supported for its use with populations with long term health conditions.
The study will use a hermeneutic single-case efficacy design and evaluate the process of change during the intervention. Following the ACT intervention, rich case records for each participant will be created using quantitative and qualitative data; this data will consist of demographic data, outcome measures and therapy material. The rich case records will be cross-referenced and amalgamated into an "affirmative" brief that presents evidence that the change can be attributed to the therapeutic intervention. The rich case record will also be analysed for indirect evidence to develop a "skeptic" brief, a brief presenting an alternative explanation for the therapeutic change. Both analyses will be evaluated through a presentation of both briefs, a rebuttal of the opposing brief and a summary narrative . The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Jessica Oshodin, MSc, BSc
- Puhelinnumero: 01522 882000
- Sähköposti: 29629594@students.lincoln.ac.uk
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Woman aged 18 or over.
- Registered with a UK GP.
- Currently under the care of or recently discharged from Nottingham or Manchester Complex Mesh Centres or have contacted their GP about mesh complications.
- Has had surgery for Stress Urinary Incontinence (SUI) and/or Pelvic Organ Prolapse (POP) and has or have had implanted polypropylene mesh causing complications.
- Experiencing self-reported psychological distress.
- Able to communicate in English.
- Has access to a device with internet access.
- Willing and able to provide informed consent for participation in the study.
- Willing to engage in psychological therapy.
Exclusion Criteria:
- ACT intervention in the past twelve months due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
- Currently engaging in psychological therapy due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
- Have insufficient command of the English language due to resources and potential impact of an interpreter on mechanism of change.
- Significant cognitive impairment.
- Current suicidal ideation for ethical and safety reasons.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Acceptance and Commitment Therapy
Participants will receive a ten-session Acceptance and Commitment Therapy (ACT) intervention |
Acceptance and commitment therapy (ACT) is a "third wave" Cognitive Behavioural Therapy that focuses on increasing psychological flexibility and acceptance of difficult experiences by undertaking value-drive actions despite psychological suffering. Psychological flexibility is developed and expanded through six core processes: acceptance, defusion, present moment awareness, self-as-context, values and committed action. Adherence to a strict protocol is not mandated for an ACT intervention; the study will be informed by an adapted ACT intervention for chronic pain (Scott et al., 2018). The intervention will reflect the heterogenous nature of mesh injury. The intervention will consist of ten individual weekly sessions lasting up to 60 minutes. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Hermeneutic Single-Case Efficacy Design - adjudication
Aikaikkuna: Through study completion, an average of 9 months.
|
The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome (Elliott et al., 2009). |
Through study completion, an average of 9 months.
|
|
Psychological distress assessed using the Clinical Outcomes in Route Evaluation 10 (CORE-10; Barkham et al., 2013)
Aikaikkuna: From baseline to the end of treatment, up to 16 weeks.
|
10-item measure designed to measure common presentations of psychological distress. The minimum value is 0 and the maximum value is 40. A higher score indicates severe distress. |
From baseline to the end of treatment, up to 16 weeks.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Mesh symptoms impact on quality of life assessed using the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol; Kelleher et al., 1997)
Aikaikkuna: From baseline to the end of treatment, up to 16 weeks.
|
20-item measure designed to measure the physical, emotional, social, and practical impact of urinary symptoms. Measure adapted to assess "mesh problem" instead of "urinary problem" (Brown, 2020). The minimum value is 0 and the maximum value is 76. A higher score indicates greater impact on quality of life. |
From baseline to the end of treatment, up to 16 weeks.
|
|
Psychological flexibility assessed using the Comprehensive assessment of Acceptance and Commitment Therapy Processes (CompACT-10; Golijani-Moghaddam et al., 2023)
Aikaikkuna: From baseline to the end of treatment, up to 16 weeks.
|
10-item short-form version of the Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT), designed to measure psychological flexibility and its core sub-processes. The minimum value is 0 and the maximum value is 60. A higher score indicates greater level of psychological flexibility. |
From baseline to the end of treatment, up to 16 weeks.
|
|
Therapeutic alliance assessed using the Session Rating Scale (SRS; Duncan et al., 2003)
Aikaikkuna: Weekly during the therapy intervention, up to 10 weeks.
|
4-item measure designed to measure the quality of the therapeutic alliance. The minimum value is 0 and the maximum value is 40. A higher score indicates greater therapeutic alliance. |
Weekly during the therapy intervention, up to 10 weeks.
|
|
Client's perception of therapy sessions assessed using the Helpful Aspects of Therapy (HAT; Llewelyn, 1988)
Aikaikkuna: Weekly during the therapy intervention, up to 10 weeks.
|
A measure designed to identify specific events that participants found most helpful during the therapy session. The minimum value is 1 and the maximum value is 9 for each scale. A higher score indicates greater helpful impact. |
Weekly during the therapy intervention, up to 10 weeks.
|
|
Change in client's goals assessed using the Personal Questionnaire (PQ; Elliott et al., 1999)
Aikaikkuna: Weekly during the therapy intervention, up to 10 weeks.
|
A measure personalised to the participant, identifying problems that the participant would like to work on in therapy. The minimum value is 7 and the maximum value is 91 for each scale. A higher score indicates greater progress towards goals/problem identified at the start of therapy. |
Weekly during the therapy intervention, up to 10 weeks.
|
|
Adherence to ACT processes measured using the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM; O'Neill et al., 2019)
Aikaikkuna: During the therapy intervention for up to 10 weeks.
|
A measure of therapist fidelity in delivering Acceptance and Commitment Therapy. The minimum value is 0 and the maximum value is 36 for ACT consistent and ACT inconsistent subscales. A higher score for the ACT consistent subscale indicates adherence to ACT processes. |
During the therapy intervention for up to 10 weeks.
|
|
Client's perception of therapy intervention and change processes assessed using the Client Change Interview (Elliott et al., 2001)
Aikaikkuna: Within two weeks of end of therapy intervention, at 12 weeks.
|
A semi-structured interview to explore the mechanism of change. |
Within two weeks of end of therapy intervention, at 12 weeks.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Danielle De Boos, ClinPsyD, University of Nottingham
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997 Dec;104(12):1374-9. doi: 10.1111/j.1471-0528.1997.tb11006.x.
- Llewelyn SP. Psychological therapy as viewed by clients and therapists. Br J Clin Psychol. 1988 Sep;27(3):223-37. doi: 10.1111/j.2044-8260.1988.tb00779.x.
- Scott W, Chilcot J, Guildford B, Daly-Eichenhardt A, McCracken LM. Feasibility randomized-controlled trial of online Acceptance and Commitment Therapy for patients with complex chronic pain in the United Kingdom. Eur J Pain. 2018 Apr 28. doi: 10.1002/ejp.1236. Online ahead of print.
- O'Neill, L., Latchford, G., McCracken, L. M., & Graham, C. D. (2019). The development of the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM): A Delphi study and field test. Journal of Contextual Behavioral Science, 14, 111-118. https://doi.org/10.1016/j.jcbs.2019.08.008
- Elliott, R., Mack, C., & Shapiro, D. A. (1999). Simplified Personal Questionnaire procedure manual. University of Toledo, Department of Psychology, Toledo, Ohio, USA.
- Duncan, B., Miller, S., Sparks, J., Claud, D.A., Reynolds, L., Brown, J., & Johnson, LD. (2003). The Session Rating Scale: Preliminary Psychometric Properties of a "Working" Alliance Measure. Journal of Brief Therapy. 3. 3-12.
- Golijani-Moghaddam, N., Morris, J. L., Bayliss, K., & Dawson, D. L. (2023). The CompACT-10: development and validity of a comprehensive assessment of acceptance an commitment therapy processes short-form in representative UK samples. Journal of Contextual Behavioral Science, 29, 59-66. doi: 10.1016/j.jcbs.2023.06.003.
- Brown JL. The experiences of seven women living with pelvic surgical mesh complications. Int Urogynecol J. 2020 Apr;31(4):823-829. doi: 10.1007/s00192-019-04155-w. Epub 2019 Dec 4.
- Barkham, M., Bewick, B., Mullin, T., Gilbody, S., Connell, J., Cahill, J., Mellor-Clark, J., Richards, D., Unsworth, G., & Evans, C. (2013). The CORE-10: A short measure of psychological distress for routine use in the psychological therapies. Counselling & Psychotherapy Research, 13(1), 3-13. https://doi.org/10.1080/14733145.2012.729069
- Elliott R, Partyka R, Alperin R, Dobrenski R, Wagner J, Messer SB, Watson JC, Castonguay LG. An adjudicated hermeneutic single-case efficacy design study of experiential therapy for panic/phobia. Psychother Res. 2009 Jul;19(4-5):543-57. doi: 10.1080/10503300902905947.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 25010
- a85xm (Rekisterin tunniste: OSF)
- 363595 (Muu tunniste: IRAS)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The results of the research study will be submitted in partial fulfilment of doctoral thesis in Clinical Psychology. A journal manuscript will be submitted to a peer-reviewed journal and any data submitted will be anonymised. Any published outputs will contain a data availability statement linked to the repository. The full dataset and any special category data will not be publicly available due to participant privacy.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .